{"id":"my008211a-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"No information is available on the mechanism of action of MY008211A tablets.","oneSentence":"MY008211A tablets' mechanism is unknown.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:20.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06050226","phase":"PHASE2","title":"A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2023-07-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":34},{"nctId":"NCT06134414","phase":"PHASE2","title":"Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2025-12","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":40},{"nctId":"NCT06932471","phase":"PHASE3","title":"Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","status":"RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-08-30","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":20},{"nctId":"NCT06932744","phase":"PHASE3","title":"Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","status":"RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-08-30","conditions":"Paroxysmal Nocturnal Haemoglobinuria (PNH)","enrollment":66},{"nctId":"NCT06933914","phase":"PHASE2, PHASE3","title":"Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-11-30","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":120},{"nctId":"NCT06687174","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-31","conditions":"IgA Nephropathy (IgAN)","enrollment":72},{"nctId":"NCT06543459","phase":"PHASE1","title":"To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-08-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":16},{"nctId":"NCT05642585","phase":"PHASE1","title":"A Study of Single-dose MY008211A in Healthy Adults","status":"COMPLETED","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2022-05-27","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":63},{"nctId":"NCT05828472","phase":"PHASE1","title":"A Study of Multiple Ascending Doses MY008211A in Healthy Adults","status":"COMPLETED","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2023-01-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":40},{"nctId":"NCT05828485","phase":"PHASE1","title":"Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2022-09-26","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["no other name","MY008211A","no name"],"phase":"phase_3","status":"active","brandName":"MY008211A tablets","genericName":"MY008211A tablets","companyName":"Wuhan Createrna Science and Technology Co., Ltd","companyId":"wuhan-createrna-science-and-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MY008211A tablets are a small molecule medication being studied in clinical trials for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and IgA Nephropathy (IgAN). The exact mechanism of action of MY008211A tablets is currently unknown.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}